How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?
暂无分享,去创建一个
J. Malvehy | P. Ascierto | P. V. Van Schil | J. V. van Meerbeeck | M. Donia | D. Dumitrascu | D. Horgan | J. A. Lal | A. Baird | T. André | L. Bertolaccini | G. Kamińska-Winciorek | P. Osterlund | Z. Mihaylova | Michael Zaiac | Marta Kozarić | J. Vogel-Claussen | M. Middleton | France Dube
[1] M. Gonen,et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. , 2022, The New England journal of medicine.
[2] J. Ptak,et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. , 2022, The New England journal of medicine.
[3] A. Roediger,et al. Should we screen for lung cancer? A 10-country analysis identifying key decision-making factors. , 2022, Health policy.
[4] A. Lallas,et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. , 2022, European journal of cancer.
[5] M. Rugge,et al. Malignant Melanoma: Direct Costs by Clinical and Pathological Profile , 2022, Dermatology and Therapy.
[6] N. Rosenfeld,et al. The future of early cancer detection , 2022, Nature Medicine.
[7] P. Bousquet,et al. The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS) , 2022, medRxiv.
[8] A. Nicholson,et al. Lung Cancer in the United Kingdom. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] S. Rudzki,et al. Title: Risk Factors for the Diagnosis of Colorectal Cancer , 2022, Cancer control : journal of the Moffitt Cancer Center.
[10] R. Dellamano,et al. P31 Impact of COVID-19 on HTA/PRMA of Medicinal Products in Europe: A Payer Perspective , 2022, Value in Health.
[11] J. Machiels,et al. Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact , 2021, Cancers.
[12] K. Nackaerts,et al. Lung Cancer in Belgium. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[13] A. Gavin,et al. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers , 2021, European journal of cancer.
[14] A. Baird,et al. The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments , 2021, Cancers.
[15] M. IJzerman. Cost of colorectal cancer care: sufficient to inform cancer policy? , 2021, The lancet. Gastroenterology & hepatology.
[16] M. Coleman,et al. The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study. , 2021, The lancet. Gastroenterology & hepatology.
[17] Pengfei Xu,et al. Global colorectal cancer burden in 2020 and projections to 2040 , 2021, Translational oncology.
[18] D. Hellwig. Hope for new developments in the reimbursement of oncological PET/CT in Germany. , 2021, Nuklearmedizin. Nuclear medicine.
[19] L. Wilson,et al. Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women , 2021, Frontiers in Oncology.
[20] R. Connolly,et al. 152P Analysis of patient access to breast cancer drugs in the USA and Europe with a focus on the UK and Ireland , 2021, Annals of Oncology.
[21] G. Veronesi,et al. Lung cancer screening: who pays? Who receives? The European perspectives , 2021, Translational lung cancer research.
[22] S. Rudzki,et al. Risk factors for the diagnosis of colorectal cancer , 2021 .
[23] R. Mroz,et al. Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2 , 2021, Contemporary oncology.
[24] M. Buljan,et al. A Reminder of Skin Cancer During the COVID-19 Pandemic. , 2021, Acta dermatovenerologica Croatica : ADC.
[25] K. Pantel,et al. Liquid Biopsy: From Discovery to Clinical Application. , 2021, Cancer discovery.
[26] C. Lebbé,et al. National early access programs and clinical trials: What opportunities for early access to therapeutic innovations for patients with malignant melanoma? , 2021, Cancer.
[27] B. Guillot,et al. Access to innovation through the national early access program and clinical trials for patients with malignant melanoma , 2021, Cancer.
[28] G. Giaccone,et al. Challenges in Diversity, Equity, and Inclusion in Research and Clinical Oncology , 2021, Frontiers in Oncology.
[29] M. Garmyn,et al. Incidence and survival of cutaneous melanoma in Belgium and the Netherlands from 2004 to 2016: striking differences and similarities of two neighbouring countries , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.
[30] S. Hua,et al. Perspectives and controversies regarding the use of natural products for the treatment of lung cancer , 2021, Cancer medicine.
[31] Adam Barsouk,et al. Epidemiology of lung cancer , 2021, Contemporary oncology.
[32] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[33] J. Kononen,et al. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study , 2021, The Lancet regional health. Europe.
[34] M. Sekerija,et al. Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer , 2021, The European Journal of Health Economics.
[35] G. Curigliano,et al. The use of liquid biopsy in early breast cancer: clinical evidence and future perspectives , 2021 .
[36] P. Giraud,et al. Lung Cancer in France. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[37] A. Kent,et al. Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine , 2020, Cancers.
[38] M. Sasiadek,et al. Personalised medicine in lung cancer , 2021 .
[39] S. Peacock,et al. Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland. , 2020, Health policy.
[40] O. Solà-Morales,et al. Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe , 2020, Breast.
[41] Shimul A. Shah,et al. Impact of the COVID-19 Pandemic on Lung Cancer Screening Program and Subsequent Lung Cancer , 2020, Journal of the American College of Surgeons.
[42] P. Hardy,et al. Clinical Applications of Nanomedicines in Lung Cancer Treatment. , 2020, Acta biomaterialia.
[43] Health at a Glance: Europe 2020 , 2020, Health at a Glance: Europe.
[44] F. Bidard,et al. Clinical utility of circulating tumor cells: an update , 2020, Molecular oncology.
[45] M. Oudkerk,et al. Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives , 2020, Nature Reviews Clinical Oncology.
[46] G. Zalcman,et al. [Epidemiology of lung cancer in France and in the world]. , 2020, La Revue du praticien.
[47] F. Bazzoli,et al. Impact of SARS-CoV-2 Pandemic on Colorectal Cancer Screening Delay: Effect on Stage Shift and Increased Mortality , 2020, Clinical Gastroenterology and Hepatology.
[48] A. Martling,et al. Improvement of colorectal cancer patient experience with a regional cancer plan in Sweden. , 2020, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[49] G. Defossez,et al. Multidimensional penalized splines for incidence and mortality-trend analyses and validation of national cancer-incidence estimates. , 2020, International journal of epidemiology.
[50] A. Testori,et al. Adjuvant Therapy for Melanoma: Past, Current, and Future Developments , 2020, Cancers.
[51] Vibeke G. Dale,et al. Lung cancer biomarker testing: perspective from Europe , 2020, Translational lung cancer research.
[52] H. D. de Koning,et al. Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe , 2020, Cancers.
[53] G. Ciliberto,et al. Propelling Health Care into the Twenties , 2020, Biomedicine Hub.
[54] G. Petrova,et al. Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries , 2020, SAGE open medicine.
[55] J. Eriksson,et al. Stated preferences for relapsed or refractory mantle cell lymphoma treatments in Sweden and Germany. , 2020, Future oncology.
[56] H. Brenner,et al. Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia–Brussels colorectal cancer screening programme , 2020, British Journal of Cancer.
[57] M. Jakovljevic,et al. A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries , 2020, Frontiers in Public Health.
[58] H. Williams,et al. Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies , 2020, BMJ.
[59] H. D. de Koning,et al. Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review. , 2020, European journal of cancer.
[60] A. Lallas,et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019. , 2020, European journal of cancer.
[61] Charline Morichon. EUROPE'S BEATING CANCER PLAN , 2020 .
[62] J. Espín,et al. Evaluation of new medicines in Spain and comparison with other European countries. , 2020, Gaceta sanitaria.
[63] G. Rossi,et al. Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. , 2019, Critical reviews in oncology/hematology.
[64] S. Simoens,et al. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! , 2019, BioDrugs.
[65] J. Jassem,et al. Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis , 2019, The oncologist.
[66] C. Signorelli,et al. Universal Health Coverage in Italy: lights and shades of the Italian National Health Service which celebrated its 40th anniversary. , 2019, Health policy.
[67] Meltem Saygılı,et al. Determining Breast Cancer Treatment Costs Using the Top Down Cost Approach. , 2019, European journal of breast health.
[68] R. Reintjes,et al. Analysis of the methodology of skin cancer incidence registration in German cancer registries , 2019, Annals of Cancer Epidemiology.
[69] R. Wood,et al. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage , 2019, BMC Cancer.
[70] M. Donia,et al. The real-world impact of modern treatments on the survival of patients with metastatic melanoma. , 2019, European journal of cancer.
[71] Prashanth Rawla,et al. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors , 2019, Przeglad gastroenterologiczny.
[72] Catriona Manville,et al. Factors affecting access to treatment of early breast cancer: Case studies from Brazil, Canada, Italy, Spain and UK: Implications for future research, policy and practice , 2019 .
[73] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[74] Carola Berking,et al. Melanoma , 2018, The Lancet.
[75] J. Gershenwald,et al. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care , 2018, Expert review of anticancer therapy.
[76] K. Straif,et al. The IARC Perspective on Colorectal Cancer Screening. , 2018, The New England journal of medicine.
[77] M. Di Maio,et al. A review of guidelines for lung cancer. , 2018, Journal of thoracic disease.
[78] W. Olszewski,et al. NSCLC molecular testing in Central and Eastern European countries , 2018, BMC Cancer.
[79] P. Potemski,et al. Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013–2016 , 2018, Melanoma research.
[80] M. Rutter,et al. Colorectal Cancer Screening—Who, How, and When? , 2018, Clinical endoscopy.
[81] K. Hata,et al. Comparison of the guidelines for colorectal cancer in Japan, the USA and Europe , 2017, Annals of gastroenterological surgery.
[82] S. Vogler,et al. Medicines reimbursement policies in Europe , 2018 .
[83] Personalised Medicine - Bringing Innovation to the Healthcare System , 2017, Biomedicine Hub.
[84] M. Buljan,et al. Health and Economic Burden of Skin Melanoma in Croatia - Cost-of-illness Study. , 2017, Acta dermatovenerologica Croatica : ADC.
[85] I. Zalaudek,et al. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. , 2017, European journal of cancer.
[86] Hiroki Nagai,et al. Cancer prevention from the perspective of global cancer burden patterns. , 2017, Journal of thoracic disease.
[87] H. Thulesius,et al. The 2015 National Cancer Program in Sweden: Introducing standardized care pathways in a decentralized system. , 2016, Health policy.
[88] G. Benčina. Metastatic Colorectal Cancer In Croatia - Cost of Disease Study , 2016 .
[89] Jie He,et al. Epidemiology of Lung Cancer. , 2016, Surgical oncology clinics of North America.
[90] C. la Vecchia,et al. Risk factors for lung cancer worldwide , 2016, European Respiratory Journal.
[91] Josep Malvehy,et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. , 2012, European journal of cancer.
[92] Hassan Lemjabbar-Alaoui,et al. Lung cancer: Biology and treatment options. , 2015, Biochimica et biophysica acta.
[93] S. Dalton,et al. Incidence of In Situ and Invasive Melanoma in Denmark From 1985 Through 2012: A National Database Study of 24,059 Melanoma Cases. , 2015, JAMA dermatology.
[94] A. Saß,et al. [Participation in cancer screening in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. , 2013, Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.
[95] Cost profiles of colorectal cancer patients in Italy based on individual patterns of care , 2013, BMC Cancer.
[96] A. Saß,et al. Inanspruchnahme von Krebsfrüherkennungsuntersuchungen , 2013, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.
[97] M. Trudeau,et al. International variability in the reimbursement of cancer drugs by publically funded drug programs. , 2012, Current oncology.
[98] M. Federico,et al. Differences in Stage and Treatment of Breast Cancer across Italy Point to Inequalities in access to and Availability of Proper Care , 2012 .
[99] D. Morton,et al. Surgery for distant melanoma metastasis. , 2012, Cancer journal.
[100] J. Becker,et al. [Treatment of advanced metastatic melanoma]. , 2011, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[101] Peter B. Gahan,et al. Overview of healthcare in the UK , 2010, EPMA Journal.
[102] B. Larsen. [Colorectal cancer screening]. , 2010, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[103] E. Winer,et al. International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? , 2010, Journal of the National Cancer Institute.
[104] L. Dušek,et al. Colorectal cancer screening in Europe. , 2009, World journal of gastroenterology.
[105] P. Kanavos,et al. Colorectal cancer management in the United Kingdom: current practice and challenges , 2009, The European Journal of Health Economics.
[106] P. Kanavos,et al. The dynamics of colorectal cancer management in 17 countries , 2009, The European Journal of Health Economics.
[107] P. Kanavos,et al. The burden of colorectal cancer: prevention, treatment and quality of services , 2009, The European Journal of Health Economics.
[108] W. Schurer,et al. Cancer management and reimbursement aspects in Germany: an overview demonstrated by the case of colorectal cancer , 2009, The European Journal of Health Economics.
[109] A. Hauschild,et al. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. , 2008, Melanoma research.
[110] K. Pantel,et al. Occult epithelial tumor cells detected in bone marrow by an enzyme immunoassay specific for cytokeratin 19 , 1997, International journal of cancer.
[111] S. Ciatto,et al. Cancer screening in the European Union. , 1994, European journal of cancer.
[112] L. Ger,et al. [Risk factors of lung cancer]. , 1992, Journal of the Formosan Medical Association = Taiwan yi zhi.
[113] S. Leff. What is Cancer , 1970 .